Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (61)	11/3/1998 9:24:00 PM
From: yosi s	Respond to of 1386

Hi I love to read all those comments. Especially since we all want Pharmos to do well. The way News releases cames out is important. Presentation is important. New abstract is news. Data that supports your finding is relevent news. How the data is received by medical community is news. At this stage Pharmos is passing from only a story stock to stock with rapidly growing revenues plus a story. If that story is not told properly we get attention on revenues, only. At this point reveues are not enough to support stock price. My concern is for the following. Does a low stock price sends a distress signal. Thus interfere with a potential deal that Pharmos can get. It is always better to be in a position of strenght. When negotiating. Price reflect market perception . So the better the price....